Literature DB >> 28013109

The impact of HTA and procurement practices on the selection and prices of medical devices.

Giuditta Callea1, Patrizio Armeni2, Marta Marsilio3, Claudio Jommi4, Rosanna Tarricone5.   

Abstract

Technological innovation in healthcare yields better health outcomes but also drives healthcare expenditure, and governments are struggling to maintain an appropriate balance between patient access to modern care and the economic sustainability of healthcare systems. Health Technology Assessment (HTA) and centralized procurement are increasingly used to govern the introduction and diffusion of new technologies in an effort to make access to innovation financially sustainable. However, little empirical evidence is available to determine how they affect the selection of new technologies and unit prices. This paper focuses on medical devices (MDs) and investigates the combined effect of various HTA governance models and procurement practices on the two steps of the MD purchasing process (i.e., selecting the product and setting the unit price). Our analyses are based on primary data collected through a national survey of Italian public hospitals. The Italian National Health Service is an ideal case study because it is highly decentralized and because regions have adopted different HTA governance models (i.e., regional, hospital-based, double-level or no HTA), often in combination with centralized regional procurement programs. Hence, the Italian case allows us to test the impact of different combinations of HTA models and procurement programs in the various regions. The results show that regional HTA increases the probability of purchasing the costliest devices, whereas hospital-based HTA functions more like a cost-containment unit. Centralized regional procurement does not significantly affect MD selection and is associated with a reduction in the MD unit price: on average, hospitals located in regions with centralized procurement pay 10.1% less for the same product. Hospitals located in regions with active regional HTA programs pay higher prices for the same device (+23.2% for inexpensive products), whereas hospitals that have developed internal HTA programs pay 8.3% on average more for the same product.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Centralized procurement; Health technology assessment; Italy; Medical devices; Price; Selection

Mesh:

Year:  2016        PMID: 28013109     DOI: 10.1016/j.socscimed.2016.11.038

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  4 in total

1.  A novel flash glucose monitoring system in patients with diabetes mellitus type 1 and 2: which are the pieces of evidence for payer decision-makers?

Authors:  Salvatore Corrao; Biagio Nativo; Giuseppe Natoli; Marika Lo Monaco; Francesco Perticone
Journal:  Intern Emerg Med       Date:  2018-05-08       Impact factor: 3.397

2.  Early Health Economic Modelling - Optimizing Development for Medical Device Developers? Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling".

Authors:  Conor Teljeur; Máirín Ryan
Journal:  Int J Health Policy Manag       Date:  2020-09-01

3.  The change of drug utilization in China's public healthcare institutions under the "4 + 7" centralized drug procurement policy: Evidence from a natural experiment in China.

Authors:  Jiancheng Lu; Hongfei Long; Yuan Shen; Jing Wang; Xin Geng; Ying Yang; Zongfu Mao; Jinghua Li
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988

4.  Laparoscopic vs open colorectal surgery: Economic and clinical outcomes in the Brazilian healthcare.

Authors:  Ulysses Ribeiro; Daiane Oliveira Tayar; Rodrigo Antonini Ribeiro; Priscila Andrade; Silvio Mauro Junqueira
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.